ATE346869T1 - Agonistische antikörper gegen tie2 - Google Patents

Agonistische antikörper gegen tie2

Info

Publication number
ATE346869T1
ATE346869T1 AT99949931T AT99949931T ATE346869T1 AT E346869 T1 ATE346869 T1 AT E346869T1 AT 99949931 T AT99949931 T AT 99949931T AT 99949931 T AT99949931 T AT 99949931T AT E346869 T1 ATE346869 T1 AT E346869T1
Authority
AT
Austria
Prior art keywords
antibodies against
agonistic antibodies
against tie2
tie2
agonistic
Prior art date
Application number
AT99949931T
Other languages
English (en)
Inventor
Stephen D Holmes
Connie L Erickson-Miller
James D Winkler
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE346869T1 publication Critical patent/ATE346869T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99949931T 1998-09-28 1999-09-28 Agonistische antikörper gegen tie2 ATE346869T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10209898P 1998-09-28 1998-09-28

Publications (1)

Publication Number Publication Date
ATE346869T1 true ATE346869T1 (de) 2006-12-15

Family

ID=22288113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99949931T ATE346869T1 (de) 1998-09-28 1999-09-28 Agonistische antikörper gegen tie2

Country Status (7)

Country Link
US (1) US6365154B1 (de)
EP (1) EP1117692B1 (de)
JP (1) JP2002525104A (de)
AT (1) ATE346869T1 (de)
DE (1) DE69934241T2 (de)
ES (1) ES2277450T3 (de)
WO (1) WO2000018804A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514434A (en) * 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7348001B2 (en) * 2003-08-12 2008-03-25 Dyax Corp. Tie1-binding ligands
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
DK1707627T3 (da) * 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
CA2576886A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
PT2076290T (pt) * 2006-10-27 2017-01-17 Sunnybrook Health Sciences Center Agonistas de tie 2 multiméricos e utilizações dos mesmos na estimulação da angiogénese
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
AU2009324354B2 (en) 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
RU2013126477A (ru) 2010-11-08 2014-12-20 Дженентек, Инк. Вводимые подкожно антитела против рецептора il-6
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
US9017670B2 (en) 2011-08-19 2015-04-28 Regeneron Pharmaceuticals, Inc. Anti-Tie2 antibodies and uses thereof
WO2013083679A1 (en) 2011-12-07 2013-06-13 Noliac A/S Piezoelectric power converter with bi-directional power transfer
EP2968541A4 (de) 2013-03-15 2017-02-08 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und deren verwendungen
DK2983695T3 (da) 2013-04-11 2019-09-02 Sunnybrook Res Inst Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister
EP3381940B1 (de) 2013-07-29 2022-09-07 Samsung Electronics Co., Ltd. Anti-ang2 antikörper
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
BR112017000689A2 (pt) 2014-07-15 2018-01-23 Astellas Pharma Inc. novo anticorpo tie-2 anti-humano
JP7264482B2 (ja) * 2016-12-23 2023-04-25 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート
EP3805265A4 (de) * 2018-06-07 2022-07-06 Institute for Basic Science An tie2 bindende antikörper und verwendungen davon
WO2019235856A1 (ko) 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
EP4061852A4 (de) * 2019-11-21 2024-03-13 Unity Biotechnology Auf tie-2 gerichtete antikörper und verwendungsverfahren
AU2021242249A1 (en) 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use
WO2022235090A1 (ko) 2021-05-06 2022-11-10 기초과학연구원 Tie2 작용제 항체 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620826A1 (de) * 1992-01-09 1994-10-26 Helsinki University Holding, Ltd. Tie, eine neuartiger tyrosinkinase-rezeptor in endothelzellen
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO1995013387A1 (en) * 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tie-2, a novel receptor tyrosine kinase
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
EP0854185A3 (de) * 1994-12-23 1998-10-21 Ludwig Institute For Cancer Research Rezeptor-Proteine zu Bestimmungszwecke und Liganden
GB9525180D0 (en) * 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions

Also Published As

Publication number Publication date
DE69934241T2 (de) 2007-05-31
EP1117692A1 (de) 2001-07-25
EP1117692B1 (de) 2006-11-29
WO2000018804A1 (en) 2000-04-06
JP2002525104A (ja) 2002-08-13
EP1117692A4 (de) 2002-11-13
DE69934241D1 (de) 2007-01-11
ES2277450T3 (es) 2007-07-01
US6365154B1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
DE69934241D1 (de) Agonistische antikörper gegen tie2
DK1047781T3 (da) IL-18-receptorer
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
ATE314371T1 (de) Spiro-indole als y5-rezeptor antagonisten
DE69837606D1 (de) Cystein-reiche rezeptoren-train
ATE458814T1 (de) Menschliches zytokinrezeptor
ATE432986T1 (de) Menschlicher rezeptor für tumor necrosis factor
AU4337699A (en) Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5HT4 receptors
ITTO991021A0 (it) Antagonisti ii del recettore ccr-3.
DE60112607T2 (de) 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten
DZ2700A1 (fr) Indoles 2,3-substitués servant d'agents anti-inflammatoires et analgésiques.
DE59800439D1 (de) Vernetzbare, in Wasser redispergierbare Pulverzusammensetzung
TR199701645A3 (tr) Vitronektin reseptör antagonistleri,bunlarin imalati ve kullanimi
DOP2001000219A (es) Applicator
NO991948D0 (no) Multi-funksjonelle, chimeriske hematopoietiske reseptorantagonister
DE60141896D1 (de) N,n'-diarylguanidine als il-8-rezeptor-antagonisten
NO20014224L (no) 4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
BR0010843A (pt) Antagonistas de receptores de il-8
BR0115856B1 (pt) composição betuminosa, e, uso da composição.
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
ITRM990083A1 (it) Sedia o simili con attrezzo ginnico incorporato.
DE69937563D1 (de) Neuer gaba-b rezeptor
IT251674Y1 (it) "perfezionamento nei dispositivi denominati idrobar,idrotuba,idrosfera e simili".
MXPA02005775A (es) Moleculas ralacionadas con el antagonista del receptor de la interleucina-1 y usos de las mismas.
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties